Cargando…

Clinical benefit in recurrent glioblastoma from adjuvant NovoTTF-100A and TCCC after temozolomide and bevacizumab failure: a preliminary observation

The NovoTTF-100A is a device that emits alternating electric fields and it is approved for the treatment of recurrent glioblastoma. It works by perturbing tumor cells during mitosis as they enter anaphase leading to aneuploidy, asymmetric chromosome segregation and cell death with evidence of increa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Eric T, Lok, Edwin, Swanson, Kenneth D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2015
Materias:	Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380964/ https://www.ncbi.nlm.nih.gov/pubmed/25620708 http://dx.doi.org/10.1002/cam4.421

Ejemplares similares

Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma
por: Wong, Eric T, et al.
Publicado: (2014)

An Overview of Alternating Electric Fields Therapy (NovoTTF Therapy) for the Treatment of Malignant Glioma
por: Swanson, Kenneth D., et al.
Publicado: (2016)

The effect of field strength on glioblastoma multiforme response in patients treated with the NovoTTF™-100A system
por: Turner, Scott G, et al.
Publicado: (2014)

NovoTTF(™)-100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL(™) system user study
por: Chaudhry, Aafia, et al.
Publicado: (2015)

PEDT-9 A study of NovoTTF-100A to expand the regulatory indication for childhood glioblastoma through a pediatric clinical trial based on the Advanced Medical Care system
por: Yuza, Yuki, et al.
Publicado: (2021)

Phase II trial of upfront bevacizumab and temozolomide for unresectable or multifocal glioblastoma
por: Lou, Emil, et al.
Publicado: (2013)

COT-23 INITIAL EXPERIENCE OF TREATMENT FOR GLIOBLASTOMA BY NOVO-TTF
por: Omura, Takaki, et al.
Publicado: (2019)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
por: Ohno, Makoto, et al.
Publicado: (2019)

Efficient production of sugar-derived aldonic acids by Pseudomonas fragi TCCC11892
por: Mao, Shuhong, et al.
Publicado: (2018)

The Role of TcdB and TccC Subunits in Secretion of the Photorhabdus Tcd Toxin Complex
por: Yang, Guowei, et al.
Publicado: (2013)

Alterations of the tumor microenvironment in glioblastoma following radiation and temozolomide with or without bevacizumab
por: Tamura, Ryota, et al.
Publicado: (2020)

Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study
por: Zhu, Ping, et al.
Publicado: (2017)

Image-based metric of invasiveness predicts response to adjuvant temozolomide for primary glioblastoma
por: Massey, Susan Christine, et al.
Publicado: (2020)

Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme
por: Shields, Lisa BE, et al.
Publicado: (2013)

Cost-effectiveness analysis of the addition of bevacizumab to temozolomide therapy for the treatment of unresected glioblastoma
por: Chen, Zhaoyan, et al.
Publicado: (2020)

ACT-21 PRIMARY EXPERIENCE OF NOVOTTF THERAPY FOR THE PATIENTS WITH GBM IN OUR INSTITUTION
por: Yamaguchi, Shigeru, et al.
Publicado: (2019)

Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin
por: Feng, Shao-Wei, et al.
Publicado: (2022)

Combined effects of niclosamide and temozolomide against human glioblastoma tumorspheres
por: Oh, Hyeong-Cheol, et al.
Publicado: (2020)

Efficacy of temozolomide and bevacizumab for the treatment of leptomeningeal dissemination of recurrent glioblastoma: A case report
por: OKITA, YOSHIKO, et al.
Publicado: (2015)

Glioblastoma Treatment with Temozolomide and Bevacizumab and Overall Survival in a Rural Tertiary Healthcare Practice
por: Carter, Tonia C., et al.
Publicado: (2018)

Temozolomide and Bevacizumab Induction before Chemoradiotherapy in Patients with Bulky Glioblastoma and/or with Severe Neurological Impairment
por: Darmon, Ilan, et al.
Publicado: (2017)

Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma
por: Adilijiang, Alimu, et al.
Publicado: (2019)

Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma
por: Lee, Eudocia Q., et al.
Publicado: (2019)

COT-19 TREATMENT EXPERIENCE OF AND TIPS FOR ADMINISTRATING NOVO TTF
por: Shimada, Daisuke, et al.
Publicado: (2019)

Computed modeling of alternating electric fields therapy for recurrent glioblastoma
por: Lok, Edwin, et al.
Publicado: (2015)

Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma—A Critical Review
por: Komotar, Ricardo J., et al.
Publicado: (2008)

Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide
por: Faustino, Alexandre Ciuffi, et al.
Publicado: (2020)

Long noncoding RNA MALAT1 knockdown reverses chemoresistance to temozolomide via promoting microRNA‐101 in glioblastoma
por: Cai, Tao, et al.
Publicado: (2018)

Identification of transcriptome signature for predicting clinical response to bevacizumab in recurrent glioblastoma
por: Choi, Seung Won, et al.
Publicado: (2018)

Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
por: Vieito, Maria, et al.
Publicado: (2022)

Phase II trial of concurrent sunitinib, temozolomide, and radiotherapy with adjuvant temozolomide for newly diagnosed MGMT unmethylated glioblastoma
por: Faye, Mame Daro, et al.
Publicado: (2023)

Upfront Bevacizumab and Temozolomide or Fotemustine before Radiotherapy for Patients with Glioblastoma and Severe Neurological Impairment at Diagnosis
por: Bihan, Celina, et al.
Publicado: (2012)

Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts
por: Nishri, Yossi, et al.
Publicado: (2022)

HGG-10. A SAFETY AND EFFICACY STUDY OF NOVOTTF-100A FOR PEDIATRIC HIGH-GRADE GLIOMA: RESULTS OF THE PLANNED INTERIM ANALYSIS OF THE FIRST THREE CASES
por: Makimoto, Atsushi, et al.
Publicado: (2023)

MCCK1 enhances the anticancer effect of temozolomide in attenuating the invasion, migration and epithelial‐mesenchymal transition of glioblastoma cells in vitro and in vivo
por: Liu, Tie, et al.
Publicado: (2019)

Photorhabdus luminescens TccC3 Toxin Targets the Dynamic Population of F-Actin and Impairs Cell Cortex Integrity
por: Dong, Songyu, et al.
Publicado: (2022)

Radiotherapy plus Concomitant Adjuvant Temozolomide for Glioblastoma: Japanese Mono-Institutional Results
por: Oike, Takahiro, et al.
Publicado: (2013)

Outcomes of pediatric glioblastoma treated with adjuvant chemoradiation with temozolomide and correlation with prognostic factors
por: Mallick, Supriya, et al.
Publicado: (2015)

Effect of long-term adjuvant temozolomide chemotherapy on primary glioblastoma patient survival
por: Huang, Bin, et al.
Publicado: (2021)

Analysis of physical characteristics of Tumor Treating Fields for human glioblastoma
por: Lok, Edwin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_g0o7n70cv7382j5kvkjcvdbs0p